Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. ASH 2018: Celgene’s Revlimid looks set for new approvals in NHL
  2. Breast cancer clinical trials: top drugs under investigation
  3. Enrollment issues are the top factor in clinical trial terminations
  4. GM babies: He Jiankui and the ethics of gene editing
  5. Pharma Technology Focus – Issue 77

Latest Content

The clinical trial landscape for GSK’s latest acquisition Tesaro

On 3 December 2018, GlaxoSmithKline (GSK) announced that it will be acquiring Tesaro to bolster its drug development portfolio, especially in oncology. With the help of GlobalData’s Pharma Intelligence Center database, a look at Tesaro’s clinical trial landscape can provide an analysis of potential R&D plans.

AbbVie halts phase III TAHOE trial of Rova-T for SCLC

Following advice from an independent data monitoring committee, biopharma company AbbVie has ceased enrolment in its TAHOE trial evaluating Rovalpituzumab Tesirine (Rova-T) as a second line therapy for patients with advanced or metastatic small-cell lung cancer (SCLC).

RAQAC

Are you a manufacturer, importer, distributor or wholesaler of healthcare products? RAQAC has the specialised knowledge to help you navigate the Canadian regulatory requirements for registering and marketing products.

Distek Model 2500 Dissolution System

The Distek Model 2500 dissolution system offers great flexibility and configurability. It
can be configured as US Pharmacopoeia (USP) Apparatus 1, 2, 5 and 6 plus intrinsic dissolution.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top